Almost 3,500 listed companies globally that have annual revenues above $1bn lost a combined $320bn in profit during periods of geopolitical and macro volatility, a study by EY-Parthenon, the strategy ...

Johnson & Johnson is making headlines with shifting analyst ratings and price target adjustments. Guggenheim raised its ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly ...

"We launched the Humankind 100 four years ago to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress," said James ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Johnson & Johnson's stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average's DJIA early gainers. Shares of rival Pfizer Inc. (PFE) were up 0.3% in premarket trades and ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape, a process that can go haywire or fail to work. But what if the body could ...